Laryngeal Diseases Clinical Trial
Official title:
Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitriptyline
Verified date | October 2021 |
Source | Boston Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized, double-blind, placebo-controlled trial will compare the effectiveness of amitriptyline versus placebo (inactive medication) in treating chronic laryngitis.
Status | Terminated |
Enrollment | 6 |
Est. completion date | January 15, 2021 |
Est. primary completion date | January 15, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Must be age 18 or older and able to consent for themselves 2. Must have had structural pathology such as tumor previously ruled out using flexible laryngoscopy 3. Must be able to speak and read the English language 4. Must have failed a 2 month or longer trial of a proton pump inhibitor for the treatment of gastro-esophageal reflux 5. Women under 55 years of age who may become pregnant must have a negative pregnancy test and agree to barrier or hormonal methods of contraception during the study 6. Potential subject and their physician have agreed that amitriptyline will be part of their regular care plan Exclusion Criteria: 1. Active untreated environmental allergies 2. Smoking within past 5 years 3. Current upper respiratory infections 4. Use of narcotics (e.g. oxycodone, methadone) within the past week 5. Hypersensitivity to amitriptyline 6. History of amitriptyline use or of other tricyclic antidepressant - including pregabalin, gabapentin, baclofen, or other gamma-aminobutyric acid (GABA)analogues or inhibitors - for any medical condition (not limited to chronic laryngitis) within the past 12 months. 7. Use of any other monoamine oxidase inhibitors (MAOIs) other than amitriptyline within the past 4 weeks (selegiline, phenelzine, tranylcypromine, isocarboxazid, rasagiline, phenelzine sulfate, selegiline hydrochloride, rasagiline mesylate, tranylcypromine sulfate) 8. History of urinary retention 9. History of an acute episode of a major depressive disorder within the past 12 months 10. For women 18-55 years of age without history of menopause: currently nursing or pregnant, plans to become pregnant, or unwillingness to utilize contraception (barrier or hormonal methods) 11. Currently participating in another clinical trial that could interfere with the efficacy of, or participation in, this study. 12. Current untreated diagnosis of gastroesophageal reflux (GERD) |
Country | Name | City | State |
---|---|---|---|
United States | Boston Medical Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Score on Reflux Symptom Index (RSI) | The Reflux Symptom Index (RSI) is a validated questionnaire consisting of 9 statements to be ranked on a scale of 0-5 (0=no problem, 5=severe problem). RSI scores can range from 0 to 45, with higher scores correlated with more reflux symptoms. | baseline, 8 weeks | |
Secondary | Change in the Score on the Voice Handicap Index-10 (VHI-10) | The Voice Handicap Index-10 (VHI-10) is a 10-question scale rated from 0-4 that addresses effects on quality of life from voice disorders (0=never, 1=almost never, 2=sometimes, 3=almost always, 4=always). VHI-10 scores can range from 0 to 40, with lower scores correlated with a higher quality of life related to voice disorders. | baseline, 8 weeks | |
Secondary | Change in the Score on the Cough Severity Index (CSI) | The Cough Severity Index is a validated 10 item questionnaire to quantify a patient's symptoms associated with upper airway chronic cough. The 4 point Likert scale for each of the 10 items is 0 to 4 where 0 = Never, 1 = Almost never, 2 = Sometimes, 3 = Almost always, 4 = Always. Scores can range from 0 to 40 and higher scores reflect more coughing. | baseline, 8 weeks | |
Secondary | Change in Throat Pain or Burning | Participants will be asked to rate the severity of their "throat pain or burning" on a scale from 0 (no problem) to 5 (severe). Higher scores are correlated with more throat pain/burning. | baseline, 8 weeks | |
Secondary | Change in Pain When Swallowing | Participants were asked to rate their pain when swallowing on a scale of 0=none to 5= severe pain. | baseline, 8 weeks | |
Secondary | Subjective Improvement of Laryngitis Symptoms | Patients will subjectively rate improvement of symptoms on an ordinal 10-point scale where 0=no improvement and 10=significant improvement. | 8 weeks | |
Secondary | Number of Participants Who Dropped Out of the Study Due to Side Effects | The number of patients who report they did not continue with study participation due to side effects, will be obtained from study logs. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02434523 -
Trial of the Treatment of Chronic Laryngitis With Amitryptiline
|
Phase 2/Phase 3 | |
Completed |
NCT01276418 -
ENT FiberLase CO2 Study
|
N/A | |
Recruiting |
NCT04575142 -
Comparison of Office-based KTP and CO2 Laser Outcomes in Patients With Vocal Cord Lesions.
|
N/A | |
Completed |
NCT02960243 -
Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres?
|
N/A |